Search Results

Authors Peter J P Croucher , Maya Ridinger , Pamela S Becker , Tara L Lin , Sandra L Silberman , Eunice

Peter Robert Banks About Dr. Peter Robert Banks Peter Banks is currently the Scientific Director at BioTek Instruments , now a part Peter Robert Banks on the web LinkedIn Dr.

J. Silvio Gutkind About this episode Dr. J. J. J. J Silvio Gutkind on LinkedIn Gutkind Lab on Twitter UCSD Moores Cancer Center Dr.

J. Silvio Gutkind About this episode Have you had moments that defined your scientific tastes? J Silvio Gutkind, a class on oncogenes and his interests for GPCRs helped shape his scientific interests J. Silvio Gutkind on the web Dr. J Silvio Gutkind on LinkedIn Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications

Nicola J. Smith About Dr. Nicola J. Smith Dr. Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function Nicola J. Smith on the web UNSW Sydney LinkedIn Retraction Watch Twitter Dr.

Paul J. Gasser About Dr. Paul J. Paul J.

Robert J. Well, it’s the one and only Robert J. Robert J.

J. Rouault About Dr. Alix A. J. reviewed the literature on the melanocortin receptor accessory protein 2 (MRAP2), resulting in my first peer-reviewed I am hopeful that my efforts to support the professional opportunities of my peers, in combination with J.

Thomas P. Sakmar About Dr. Thomas P. Thomas P.

= 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032 ) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb. Nemirovsky, Andriy Derkach, Bruno Almeida Costa, Noriko Nishimura, Tasmin Farzana, Colin Rueda, David J Chung, Heather J Landau, Oscar B Lahoud, Michael Scordo, Gunjan L Shah, Hani Hassoun, Kylee Maclachlan

selective 5-HT1A receptor agonists Date & Time Saturday, November 4th / 9:05 AM Abstract Coming Soon About Peter Peter Gmeiner received his Ph.D. from the University of Munich. Peter has been chaired Full Professor of Pharmaceutical / Medicinal Chemistry at the Friedrich-Alexander Peter Gmeiner has been spokesman of the Research Training Group "Medicinal Chemistry of Selective GPCR Ligands" (GRK 1910). " Peter Gmeiner on the web Friedrich Alexander University Erlangen-Nürnberg Pubmed

Authors Nick D Bergkamp , Jeffrey R van Senten , Hendrik J Brink , Maarten P Bebelman , Jelle van den Bor , Tuğçe S Çobanoğlu , Kasper Dinkla , Johannes Köster , Gunnar Klau , Marco Siderius , Martine J

Authors Jillian G Baker, Erica K Sloan, Kevin Pfleger, Peter J McCormick, Cristina Salmerón, Paul A Insel

Carter , Nicolas Jaime Roth , Jessica Gibson , Ariana Samadi , Hemant M Kocher , Sabrina Simoncelli , Peter J McCormick , Richard Philip Grose Tags cancer biology , cell biology , human.

Bryan S Yung , Farhoud Faraji , Robert Saddawi-Konefka , Zhiyong Wang , Alexander T Wenzel , Miranda J Rebecca Berdeaux , Dario A A Vignali , Ramiro Iglesias-Bartolome , Hannah Carter , Eytan Ruppin , Jill P Mesirov , J Silvio Gutkind .

Authors Bikash Chandra Jena, Daniel P Flaherty, Valerie P O'Brien, Val J Watts Tags Adenylyl Cyclase

Chenlin Feng, Rongfang Liu, Reno Brooks, Xuesong Wang, Willem Jespers, Marina Gorostiola González, Gerard J P van Westen, Erik H J Danen, Laura H Heitman Tags 5-HT(2C) receptor , G protein-coupled receptor , cancer

Authors Stephen A Chetwynd, Richard J Ward, Graeme Milligan, Heidi C E Welch Tags C5aR1 , CXCR4 , G protein-coupled receptor (GPCR) , GPCR trafficking , Ncdn , Neurochondrin , P-Rex1 , agonist-induced internalisation

Targeted and Immunotherapies Date & Time Friday, November 3rd / 3:30 PM Abstract Coming Soon About J. J.

higher in the case group as compared to the control group (positivity 40.31 ± 3.01 vs. 20.46 ± 1.93, p < 0.001; density 2.77 ± 1.17 vs. 1.28 ± 0.37, p < 0.001). mRNA level was also upregulated in patients compared to the controls (2.36 ± 1.30 vs. 1.09 ± 0.42, p < 0.001) and showed a positive correlation with immunostaining of protein in OSCC (r = 0.48, p = 0.011 differentiation (p = 0.013), clinical TNM stages (p = 0.014), and poor survival (p = 0.006) of patients

By the end of 2021, I moved back to Germany and joined the pharmaceutical chemistry group of Peter Kolb

Low PAXIP1-AS1 expression in OC was associated with age (P = 0.045), histological grade (P = 0.011), and lymphatic invasion (P = 0.004). Low PAXIP1-AS1 expression predicted a poorer overall survival (OS) (HR: 0.71; 95% CI: 0.55-0.92; P = survival (DSS) (HR: 0.67; 95% CI: 0.51-0.89; P = 0.006). PAXIP1-AS1 expression (HR: 0.711; 95% CI: 0.542-0.934; P = 0.014) was independently correlated with PFS

Authors Guangrong Qin, Jin Dai, Sylvia Chien, Timothy J Martins, Brenda Loera, Quy H Nguyen, Melanie L Oakes, Bahar Tercan, Boris Aguilar, Lauren Hagen, Jeannine McCune, Richard Gelinas, Raymond J Monnat

Seufert2, Yin Kwan Chung3, Daniela Volke1, Ralf Hoffmann1, Torsten Schöneberg4, Tobias Langenhan3, Peter Authors & Affiliations "Garbett, Krassimira, Kordon, Szymon P., Shearer, Tanner, Sando, Richard C.*, Chung, Yin Kwan2, Pohl, Fabian2, Batebi, Hossein1 Sträter, Norbert3 , Langenhan, Tobias2 & Hildebrand, Peter

β1 AR) , M5-muscarinic (M5AR), and angiotensin II type 2 receptors (AT2R) were increased in HF (all P against α1 -adrenergic (α1 AR) and angiotensin II type 1 receptors (AT1R) were decreased in HF (all P < 0.05) and global longitudinal strain (r = -0.323, P < 0.05). In insulin-resistant HF patients, AT2R autoantibodies were decreased (r = -.240, P < 0.05), and AT1R autoantibodies were increased (r = 0.212, P < 0.05).

to promote the expressions of GPRC5A compared with those of the NC group (1.00±0.01, 1.00±0.00)(all P< increase of GPRC5A at both gene and protein levels induced by LPS (1.30±0.10, 1.43±0.03) (F=208.38, P< 0.001; F=42.04, P<0.001). PTGS2 at the gene level in LPS group were highly increased compared with those in the NC group (all P< in the NC group, and siGPRC5A could effectively suppressed LPS-induced protein phosphorylation (all P<

of evaluated autoantibodes were significantly higher in Long-COVID compared to the 2 other groups (p higher number of patients with simultaneous detection of more than one autoantibody in Long-COVID group (p ARB1 and ARB2 correlated negatively CERAD Trail Marking A and B (R ≤ -0.26, p ≤ 0.043), while CHRM3 correlated positively with Chadler Fatigue Scale (R = 0.37, p = 0.0087).

patients receiving CLAG-M/sorafenib at RP2D (OS: hazard ratio,0.24 [95% confidence interval, 0.07-0.82]; P = .023; EFS: hazard ratio, 0.16 [95% confidence interval, 0.05-0.53]; P = .003). Benefit was limited to patients with intermediate-risk disease (univariate analysis: P = .01 for OS; P = .02 for EFS).